Matt Hoffman, Associate Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments® podcast, as well as the Medical World News show, Deep Dive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com
Tremeau Pharmaceuticals Gets IND Go-Ahead for Rofecoxib Reformulation, Dubbed TRM-201
June 15th 2022The oral tablet formulation of rofecoxib has been shown to reach maximum plasma concentrations at 2 hours post dose compared with 3 for the historical formulation, which the company believes can improve the time to onset of action.
Children, Adolescents With Migraine Show High Risk for Anxiety and Depression Symptoms
June 14th 2022A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.
Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence
June 11th 2022Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.
Rimegepant Is Well-Tolerated and Safe for Migraine Over 1 Year With Every-Other-Day Dosing
June 10th 2022Patients in the open-label extension also showed limited need for acute treatment with rimegepant (Nurtec ODT; Biohaven Pharmaceuticals), as more than 80% of patients took 16 or fewer total tablets over the 28-day period.
FibroGen Completes Enrollment in LELANTOS-2 Trial of Pamrevlumab in Ambulatory DMD
June 9th 2022The trial is set to read out topline data in the second half of 2023 after completing the target enrollment of 73 patients with Duchenne muscular dystrophy aged 6 to 12 years. The connective tissue growth factor inhibitor has been granted orphan drug, fast track, and rare pediatric disease designations.
Clinical Care Effects of Risdiplam’s Expanded Indication in SMA
June 8th 2022Richard Finkel, MD, RAINBOWFISH’s principal investigator and the director of the Experimental Neuroscience Program at St. Jude Children’s Research Hospital, offered his take on the recent FDA decision for risdiplam (Evrysdi; Genentech).
EHR-Incorporated MS Smartform Significantly Cuts Down Patient History Review Time in MS
June 2nd 2022The form, which is freely available through the Epic and Cerner EHR platforms, was developed to streamline and standardize patient data collection to allow clinicians more time with patients and more consistent information.
Women With MS Utilize Social Media to Discuss, Share Safety Concerns on DMT Use During Pregnancy
June 1st 2022Investigators utilized a social media listening tool to evaluate and scale mentions of disease-modifying therapy use by women with multiple sclerosis, with the majority of concerns focused on safety and treatment reinitiation in the postpartum period.
The Future of Care and Focusing on Brain Health in MS to Maximize Reserve
May 30th 2022Stephen Krieger, MD, of the Icahn School of Medicine and Corinne Goldsmith Dickinson Center for MS at Mount Sinai, shared his perspectives on the trends in multiple sclerosis and the need to holistically treat patients to maximize brain reserve.